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advances in mechanistic understanding of apoptotic path-
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 Introduction 
 Neutrophils are the most abundant cells of the innate 
immune system and are major players in the body’s fight 
against infection. Neutrophils release a cytotoxic and 
proteolytic cocktail that allows effective killing of invad-
ing micro-organisms. Neutrophils and their armamen-
tarium contribute significantly to the inflammatory re-
sponse in normal physiology and there are important 
regulatory mechanisms that allow limitation and resolu-
tion of this response  [1, 2] . Apoptosis, a programmed cell 
death that occurs to conserve toxic neutrophil contents, 
is one such mechanism. The apoptotic cell undergoes 
several characteristic alterations ( fig. 1 ), including alter-
ation of cell surface markers (e.g. increased expression of 
phosphatidylserine) that help phagocytes, such as mac-
rophages, to clear them  [3] . Apoptosis and the subse-
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 Abstract 
 Neutrophils are the most abundant cell type involved in the 
innate immune response. They are rapidly recruited to sites 
of injury or infection where they engulf and kill invading mi-
croorganisms. Neutrophil apoptosis, the process of pro-
grammed cell death that prevents the release of neutrophil 
histotoxic contents, is tightly regulated and limits the de-
structive capacity of neutrophil products to surrounding tis-
sue. The subsequent recognition and phagocytosis of apop-
totic cells by phagocytic cells such as macrophages is central 
to the successful resolution of an inflammatory response 
and it is increasingly apparent that the dying neutrophil it-
self exerts an anti-inflammatory effect through modulation 
of surrounding cell responses, particularly macrophage in-
flammatory cytokine release. Apoptosis may be delayed, in-
duced or enhanced by micro-organisms dependent on their 
immune evasion strategies and the health of the host they 
encounter. There is now an established field of research 
aimed at understanding the regulation of apoptosis and its 
potential as a target for therapeutic intervention in inflam-
matory and infective diseases. This review focuses on the 
physiological regulation of neutrophil apoptosis with re-
spect to the innate immune system and highlights recent 
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quent phagocytosis of apoptotic cells is central to suc-
cessful resolution of inflammation and there is signifi-
cant research interest in targeting apoptosis as a means 
to treat neutrophil-dominant, inflammatory diseases 
 [4] . It is also apparent that in inflammatory disease there 
are several ways in which this regulatory mechanism can 
be compromised  [1] . There is also increasing evidence 
that the neutrophil can contribute significantly to the 
inflammatory process through expression and release of 
factors that influence the behaviour of other cell types, 
particularly those involved in promoting resolution of 
inflammation  [5] . The apoptotic neutrophil and the pro-
cess of cell death exert anti-inflammatory effects that 
have been shown to be of therapeutic value in inflamma-
tory disease models. In addition to pharmacological ma-
nipulation of the apoptotic pathway (e.g. by using cyclin-
dependent kinase (CDK) inhibitors  [6] ), the systemic ad-
dition of apoptotic neutrophils (made apoptotic ex vivo) 
has also enhanced survival in animal models of sepsis  [7] 
 as a result of the LPS-binding capacity of apoptotic neu-
trophils and the subsequent clearance of these cells by 
macrophages. The benefits of apoptotic neutrophils are 
twofold as they also stimulate macrophages into a pro-
resolution phenotype, reducing the inappropriate in-
flammatory response further. This is an excellent exam-
ple of an apoptosis-based strategy proving beneficial in 
a model of excessive host response to microbial infection. 
The apoptotic pathway can be targeted by microbes that 
promote neutrophil death as well as those that extend 
neutrophil longevity in order to avoid provoking an ear-
ly immune response  [8] . It is increasingly important to 
consider the mechanistic insights that may be gleaned 
from an understanding of appropriate innate immune 
system responses, their subversion and the inappropriate 
or excessive response which has been described in non-
infectious inflammatory diseases. This is especially true 
in the design of anti-microbial and anti-inflammatory 
therapeutic agents, and it is clear that there is much to be 
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 Fig. 1. Demonstration of neutrophil apoptosis by live-cell imaging 
using confocal microscopy. Neutrophil apoptosis induced by the 
cyclin-dependent kinase inhibitor R-roscovitine. Neutrophil with 
intact mitochondria fluorescing red ( a ). Neutrophil has rounded 
up ( b ) before blebbing occurs ( c ) and mitochondrial dissipation 
with green fluorescence throughout the cytoplasm ( d ). Annexin-
V binding to exposed phosphatidylserine residues is shown by 
green fluorescence at cell periphery ( e ) followed by secondary ne-
crosis with PI entering cell nucleus ( f ), and then spreading through 
the cytoplasm ( g ), presumably with nuclear membrane disrup-
tion. 
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gained from collaborative work between microbe-cen-
tred researchers and those interested in inflammatory 
cell apoptosis.
 Role of the Neutrophil in Inflammation 
 Neutrophils are part of the granulocyte family of leu-
kocytes that also include eosinophils and basophils. They 
are termed granulocytes because of the small packages 
(granular in appearance) of preformed proteins that 
adorn their cytoplasm and help to define their morphol-
ogy histologically. Several types of granules exist within 
neutrophils: secretory, primary, secondary, and tertiary 
granules. Over 300 proteins are contained within the 
granules that are involved in many neutrophil processes 
including: adhesion, migration and anti-bacterial activi-
ties  [9] . The secretory vesicles are of endocytic origin and 
are the first to be mobilised to facilitate neutrophil re-
cruitment and migration. They contain a reservoir of 
membrane proteins that are incorporated into the neu-
trophil outer membrane following vesicle release to pro-
mote the inflammatory response. The   -integrins, com-
plement receptor 1 (CR1), CD14, CD16, and formyl pep-
tide receptors are all upregulated on the neutrophil 
membrane following secretory vesicle activation. Signifi-
cant concentrations of heparin-binding protein (HBP) 
can be found following secretory vesicle activation and is 
thought to act as a monocyte chemoattractant which has 
important implications for the resolution of the inflam-
matory response  [10] .
 Tertiary and secondary granules are the next granules 
to be mobilised, followed finally by the primary granules. 
This coordinated and timely release of different granule 
subsets allows for the appropriate response to be mount-
ed at the right time and minimises the destructive poten-
tial of the neutrophil. The primary or azurophilic gran-
ules are responsible for the majority of anti-microbial
effectors, containing alpha-defensins and the serine
protease, elastase.
 Mature neutrophils are terminally differentiated, non-
dividing cells that develop from CD34+ pluripotent stem 
cells in the bone marrow under the direction of various 
colony stimulating factors (CSFs) including IL-3, granu-
locyte-CSF (G-CSF) and granulocyte macrophage-CSF 
(GM-CSF)  [11] . Many of these continue to influence neu-
trophil longevity outside of the bone marrow and Kuij-
pers et al. [12] have shown changes at gene level promoted 
by G-CSF in terminally differentiated neutrophils. Neu-
trophils are released into the systemic circulation where 
they form the majority of the circulating leukocyte cell 
population. There is also a ‘marginated’ population of 
mature neutrophils found in the microvasculature of 
many tissues including, for instance, the lung as well as a 
population resident in the spleen (the ‘splenic pool’). Un-
der normal conditions the number of mature neutrophils 
remains fairly constant, but during pro-inflammatory 
episodes (e.g. infection), these can be increased in the cir-
culation by up to 10-fold. Rapid demargination, along 
with increased bone marrow production, occurs in re-
sponse to increased levels of soluble inflammatory fac-
tors. Upon encountering inflammatory signals, neutro-
phils change their responsiveness dramatically to allow 
directed migration and enhancement of microbicidal ca-
pacity. Once at the site of infection, neutrophils unleash 
their arsenal of toxic products to kill and clear invading 
pathogens by the processes of phagocytosis, degranula-
tion and generation of reactive oxygen metabolites (e.g. 
superoxide anion). In addition, there is substantial evi-
dence that neutrophils change their phenotype following 
a successful response from a pro-inflammatory state 
where they produce and release pro-inflammatory me-
diators such as LTB 4 and PAF to a more anti-inflamma-
tory pro-resolution state whereby they release products 
(e.g. lipoxins) that can influence the resolution phase of 
inflammation  [13, 14] . Indeed, further recent evidence to 
suggest that the neutrophil is more plastic than once ap-
preciated has been described. For example, tumour-as-
sociated neutrophils can polarize into two phenotypes; 
an anti-tumorigenic (N1) or pro-tumorigenic (N2) phe-
notype under the regulation of TGF-   [15] . In addition, 
it has been suggested that mature neutrophils may trans-
differentiate into macrophage-like cells  [16] . A controver-
sial finding that is nonetheless intriguing despite being 
reliant on quite specific in vitro conditions.
 Under normal conditions, circulating neutrophils have 
a short half-life (7–12 h in vivo) and are generally func-
tionally quiescent. It is believed that circulating neutro-
phils either home to the spleen, liver or back to the bone 
marrow to be destroyed  [17] or alternatively leave the cir-
culation to infiltrate tissues. Neutrophil life-span is dy-
namically influenced during inflammation to enhance 
the anti-microbial action of the neutrophil. This is typi-
fied by the increased half-life of neutrophils stimulated 
with inflammatory agents such as LPS  [18, 19] . Once their 
physiological function has been fulfilled in the tissues 
(e.g. destruction of invading organisms), they undergo 
spontaneous apoptosis, a programmed cell death that oc-
curs to preserve neutrophil membrane integrity and pre-
vent the uncontrolled release of toxic cell contents. Apop-
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tosis-specific cell changes promote the recognition and 
uptake of cells by phagocytes such as macrophages. The 
resolution of inflammation therefore relies on the effec-
tive ‘switching off ’ of the neutrophil, the promotion of 
apoptosis and the successful clearance of these cells. 
 There are two main mechanisms that account for the 
powerful microbicidal properties of neutrophils: the pro-
duction and reaction of free radical species, and the co-
ordinated release of proteolytic and anti-microbial gran-
ule contents. Neutrophils and other phagocytes are 
uniquely equipped with the NADPH oxidase enzyme 
that when activated, catalyses the transfer of electrons
to molecular oxygen to produce the superoxide anion, a 
highly reactive free radical with powerful antimicrobial 
properties. This process, referred to as the respiratory 
burst, occurs in response to soluble inflammatory factors 
or following phagocytosis. The free radicals can be re-
leased outside the cell, or within the cell in the phago-
some, the internalised compartment containing ingested 
material. Other reactive oxygen species are readily formed 
following superoxide release. In the phagosome, superox-
ide rapidly reacts to form hydrogen peroxide, another 
powerful oxidant with antimicrobial effects. Other reac-
tive oxygen metabolites, such as nitric oxide and per-
oxynitrite, can also form depending on the presence of 
substrates and/or quenching anti-oxidant load within the 
inflammatory milieu. The importance of the respiratory 
burst to the microbicidal effects of neutrophils is under-
pinned by the clinical features of chronic granulomatous 
disease (CGD), which is caused by a rare, inherited muta-
tion in one of the subunits of the NADPH oxidase en-
zyme that renders the cell incapable of producing super-
oxide. As a result, these patients suffer from recurrent 
bacterial and fungal infections and develop characteris - 
tic granulomas (typical of unresolved antimicrobial re-
sponse) in their organs. 
 The release of granule contents, particularly those of 
the primary and secondary granules have significant an-
timicrobial actions. The granules contain an abundance 
of proteins and enzymes including myeloperoxidase 
(MPO), lysozyme, lactoferrin, hCAP18 and NGAL. The 
cathelicidins are an evolutionary conserved family of 
peptides that have well characterised antimicrobial and 
immunomodulatory actions. The human cathelicidin, 
LL-37, formed from proteolytic cleavage of hCAP-18
following its release from neutrophil-specific granules, is 
found in high concentrations during infection. It is read-
ily detectable in saliva and lung secretions reflecting its 
importance in the first line of defence against pathogens 
in these ‘high contact’ areas. As well as antimicrobial ac-
tion against bacteria, fungi and viruses, LL-37 has also 
been shown to have important immunomodulatory ef-
fects including chemotactic and endotoxin-neutralising 
properties (see below). The most abundant granule en-
zyme is MPO, which forms cytotoxic hypochlorous acid 
(HOCl) from the reaction of chloride anion with hydro-
gen peroxide produced after the respiratory burst. MPO 
also oxidises tyrosine residue to form another cytotoxic 
species, the tyrosyl radical. This enzyme has a heme pros-
thetic group, which gives it a green pigment that can be 
seen in neutrophil-rich secretions such as pus and mu-
cous. There is now evidence that suggests MPO can act 
as a paracrine signalling molecule, promoting neutrophil 
survival through its binding to the   2 integrin and sub-
sequent activation of second messenger pathways  [20] . 
 Granulocyte Apoptosis 
 The mechanisms that drive granulocyte apoptosis have 
been extensively reviewed  [1, 2, 21] . There are a number of 
key distinguishing features of neutrophil apoptosis. The 
pre-eminence of the Bcl-2 homologue Mcl-1  [22] as a sur-
vival protein preventing intrinsic apoptosis is central to 
the neutrophil’s capacity to undergo rapid apoptosis and 
is probably responsible for the limitation of neutrophil 
longevity to 24–36 h. Mcl-1 is an unusual bcl-2 protein in 
that it has a PEST domain (rich in proline (P), glutamic 
acid (E), serine (S), and threonine (T)) which means it can 
be rapidly turned over in the proteasome giving it a very 
short half-life of approximately 2 h  [23–25] . This is in con-
trast to the key pro-apoptotic bcl-2 homologues, thought 
to be Bax  [26, 27] , Bid  [28] and Bim  [29, 30] which can 
persist in the cell beyond 12 h. Bim has recently and some-
what counter-intuitively been shown to be upregulated by 
pro-survival factors such as GM-CSF and IL-3, the pre-
sumption being that it acts as a physiological brake on 
cytokine-enhanced longevity  [29] . It is not surprising that 
a critical excess of pro- as opposed to anti-apoptotic bcl-2 
homologues is a perpetual Damocles’ sword hanging over 
neutrophil fate. This eventuality leads to loss of mitochon-
drial potential (probably achieved by the formation of 
pores in the outer mitochondrial membrane by pro-apop-
totic bcl-2 homologues) and the progression of apoptosis 
as shown in  figures 1 and  2  [31] . Other interesting facets 
of neutrophil apoptosis include the dual effects of TNF-  
on survival and extrinsic apoptosis  [32, 33] . TNF-  drives 
early neutrophil apoptosis (as early as 2 h after treatment) 
by triggering the extrinsic pathway ( fig. 2 ) but promotes 
late survival (beyond 24 h) by initiating the NF-  B path-
 Fox/Leitch/Duffin/Haslett/Rossi J Innate Immun 2010;2:216–227220
way, the sine qua non of neutrophil inflammatory signal-
ling, leading to transcription of survival proteins includ-
ing XIAP and A1  [34] . The extrinsic and intrinsic apop-
totic pathways are linked by caspase-8 cleavage of Bid 
( fig. 2 ) in type II apoptosis cells, such as neutrophils, 
which has important implications for the experimental 
demonstration of apoptotic mechanism. Traditionally, it 
has been assumed that this led to activation of procaspase 
9 via the apoptosome, though a recent study has suggested 
that the key feature may be inhibition of XIAP by Smac 
leading to procaspase-3 activation  [35] . It has been sug-
gested that this may be the critical determinant of type II 
apoptosis as opposed to type I. For a more comprehensive 
overview of the investigation of apoptosis and appropriate 
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 Fig. 2. Neutrophil apoptosis. Extrinsic apoptosis as typified by 
apoptotic pathway triggering by TNF-  or Fas ligand (TNF-  de-
picted). Extrinsic apoptosis proceeds via clustering and cleavage 
of procaspase-8. In neutrophils (and other type II apoptotic cells) 
it is linked to the intrinsic apoptotic (or mitochondrial) death 
pathway by cleavage of the pro-apoptotic bcl-2 homologue Bid. 
The intrinsic pathway is initiated when the tightly regulated bal-
ance of bcl-2 homologue proteins tips in favour of pro-apoptotic 
proteins such as Bim, Bad, Bax and Bak. Also shown is the anti-
apoptotic function of TNF-  which mediates production of sur-
vival proteins via NF-  B signalling. The key anti-apoptotic Bcl-2 
homologue in neutrophils is Mcl-1 which is regulated by a number 
of signalling pathways (created using SABIOscience presentation 
tools). 
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nomenclature, see the following reviews  [36, 37] . Other 
points of interest include the role given to reactive oxygen 
species (ROS) in initiating apoptosis by activation of pre-
formed lipid raft clustered apoptotic machinery  [38] and 
the existence of neutrophil deficiency syndromes such as 
severe congenital neutropenia or disorders of neutrophil 
impairment where apoptosis is affected by the absence
of ROS generation (chronic granulomatous disease), or 
granule formation (Chediak-Higashi)  [39] . Additionally, 
neutrophils are now noted to undergo a novel and NADPH 
oxidase-dependent form of cell death ‘NET-osis’ which 
was thought to be the inextricable sequelae of the produc-
tion of antimicrobial NETs  [40] . An alternative outcome 
has been suggested by a study showing that neutrophils 
can form NETs from mitochondrial DNA and subse-
quently remain viable  [41] . Neutrophil death is highly reg-
ulated on a constitutive basis and in response to pathogens 
the complexity increases, so that it is often difficult to de-
cide which death-modality is most favourable from a host 
perspective.
 Pathogens and Neutrophil Apoptosis  
 The physiological role of neutrophils is directed to-
wards the eradication of invading pathogens that have 
breached front-line structural immune defence  [1] . A 
massive neutrophil influx may occur in response to the 
detection of pathogen elements or signalling from tissue 
cells that have encountered pathogens (mainly tissue 
macrophages). A successful response should result in the 
eradication of the culprit micro-organism and the resto-
ration of tissue homeostasis. Neutrophil apoptosis can 
play a decisive role in either a positive or negative out-
come as might be expected from the ancient and intricate 
interplay of host-pathogen response interaction  [8, 42] .
 A model in which neutrophil apoptosis can play a 
strong positive role is that of  Streptococcus pneumoniae 
pneumonia  [43] . In this condition, a comprehensive but 
contained neutrophil influx results in the phagocytosis 
of the bacteria and destruction within the neutrophil 
phagosome. Phagocytosis primes the neutrophil to un-
dergo apoptosis; a response that has been termed phago-
cytosis-induced cell death (PICD)  [44] . This is a benefi-
cial occurrence as it effectively prevents further path-
ogen movement. A dead cell should be more difficult to 
hijack and use as a Trojan horse by hostile invaders  [45] . 
Apoptotic neutrophils are then cleared by resident and 
recruited macrophages as well as tissue epithelial cells. 
This clearance prevents neutrophils from progressing to 
secondary necrosis and the potential for bystander tissue 
damage. It also provides a second opportunity for patho-
gen destruction as apoptotic cells and debris are further 
digested and disposed of.
 However, there are striking examples of subversion of 
this process by many pathogens including:  Chlamydia 
pneumoniae  [46, 47] ,  Pseudomonas aeruginosa  [48] and 
 Staphylococcus aureus  [49] . It is important to note that the 
effects of pathogens on neutrophils in experimental mod-
els are dependent on a number of variables which can 
mean that directly opposing (and potentially equally val-
id) results may be obtained. Key variables like bacterial 
multiplicity of infection (MOI), bacterial strain, duration 
of exposure, cell preparation and purity may influence 
neutrophil longevity. It has previously been shown that 
high MOIs lead to neutrophil apoptosis whilst low MOIs 
stimulate longevity  [50] .
 C. pneumoniae , an obligate intracellular pathogen and 
cause of community-acquired pneumonia can survive 
and even multiply inside human neutrophil granulo-
cytes. Once inside the neutrophil,  C. pneumoniae is un-
willing to relinquish its obliging host and compels the 
neutrophil to an extended longevity of up to 90 h  [46] . 
This effect appears to be mediated both by bacterial LPS 
and enhanced neutrophil production of IL-8 acting in 
both an autocrine and paracrine manner. These effects 
are not permanent and the neutrophil does eventually 
undergo apoptosis and phagocytosis by a macrophage. 
Unfortunately, the macrophage becomes the unwitting 
host of the  C. pneumoniae organism, and because it has 
been internalised without exposure to surface receptors, 
an inappropriate response is generated  [47] . Instead of 
recognising the micro-organism as non-self and respond-
ing phlogistically, the macrophage merely registers up-
take of an apoptotic cell, an input that generates an anti-
inflammatory phenotype and prevents macrophage ac-
tivation  [51] . It has now been shown that this process 
probably facilitates infection of epithelial cells by  C. pneu-
moniae as bugs that were directly ingested by macro-
phages, as opposed to consumed within an apoptotic cell, 
were at least contained, even if not killed  [47] . 
 Another organism that is increasingly recognised to 
modulate neutrophil apoptosis is  S. aureus . Despite clin-
ical evidence, arising from the increased susceptibility of 
patients with the immune-deficiency syndromes dis-
cussed above, suggesting that the main effector arm of 
the immune response to  S. aureus is the neutrophil, this 
organism can induce survival, apoptosis or necrosis in 
different contexts  [49] . Survival appears to be conferred 
by enhanced production of the cytokines IL-6 and IL-1  
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which suggests that there may be a paracrine effect on 
surrounding tissue cells with feedback of survival signals 
 [50, 52, 53] .
 While the neutrophil proves relatively resistant to 
staphylococcal haemolysins, delta haemolysin has been 
shown to prime and even directly activate (in the presence 
of LPS/TNF) neutrophils which (depending on the extent 
of activation) may prolong or curtail neutrophil life-span. 
Currently, the most infamous staphylococcal toxin is Pan-
ton-Valentine leucocidin toxin (PVL) because of MRSA 
strains bearing this toxin that can cause severe necrotising 
pneumonia in previously healthy individuals. PVL at low 
concentrations promotes the formation of pores in neutro-
phil mitochondrial membranes promoting classical mito-
chondrial apoptosis, whilst at high concentrations cell 
membranes are rendered porous promoting necrosis  [55] . 
It has also been suggested that PVL might promote neutro-
phil activation. This combination of excessive, ineffectual 
activation and decreased longevity with a further sugges-
tion that the bactericidal activity of neutrophils is simulta-
neously disarmed by downregulation of oxidative burst 
capacity makes for a ruinous mix of persistent infection 
and inflammation-driven tissue necrosis  [49] .
 Pseudomonas aeruginosa, a pathogen associated with 
cystic fibrosis and ventilator-associated pneumonia, al-
most completely dismantles the innate immune defence 
paradigm discussed earlier. In addition to evading killing 
by promoting neutrophil apoptosis through production 
of the toxin pyocyanin, it also inhibits macrophage clear-
ance of apoptotic cells leading to secondary necrosis and 
tissue destruction  [48, 54] . The immune system is then 
forced to defend the indefensible as the tissue environ-
ment is subverted to the ends of the bacterium.  P. aerugi-
nosa can effectively hide away from subsequent immune 
sallies through the synthesis of a protective biofilm. It is 
clear that specific micro-organisms utilise a variety of 
immune evasion/immune thwarting strategies and it will 
always be important to consider this when designing nov-
el anti-microbial and anti-inflammatory strategies.
 Many different organisms may be implicated in the 
development of sepsis (pathogens present in peripheral 
circulation with characteristic physiological changes) 
and the potential sequelae of septic shock and adult re-
spiratory distress syndrome (ARDS)  [1] . Neutrophils 
have been shown to be functionally downregulated in a 
recent study of septic ITU patients where various caus-
ative pathogens were isolated  [56] . In this study, C5a was 
implicated mechanistically in the inhibition of wide-
ranging neutrophil functions including: phagocytosis, 
chemotaxis and superoxide anion production. This is in 
almost complete contrast to previous work on the role of 
this component of the complement cascade which is usu-
ally thought of as a chemoattractant and neutrophil ac-
tivator. The ARDS is arguably an example of an exces-
sive, even inappropriate activation of the innate immune 
response with potentially fatal consequences. Inflamma-
tion is a necessary immune defence mechanism; how-
ever, the inflammatory response can become sustained 
or self-perpetuating if it fails to remove the provoking 
stimulus or if the mechanisms of resolution become dys-
functional. Increased production of cytokines and con-
tinued release of proteolytic and cytotoxic contents by 
abundant cell infiltrates increase tissue damage associ-
ated with acute and chronic inflammatory disorders in-
cluding: ARDS, ILD, cystic fibrosis, COPD, and arthri-
tis. It is clear that inducing the resolving phase of inflam-
mation through cytokine-neutralising therapies (e.g. 
anti-TNF-  , anti-CD20 in inflammatory skin disease 
and arthritis) can be of therapeutic benefit  [57, 58] . There 
is now encouraging evidence from animal models that 
the promotion of neutrophil apoptosis may drive resolu-
tion of inflammation both by promoting a favourable 
pro-resolution cytokine mix and removing the respon-
sible inflammatory effector cell  [6, 7] . In addition, there 
is increasing understanding of the mechanisms used by 
pathogens to subvert apoptotic machinery in neutrophils 
and evidence that a combination of anti-bacterial thera-
py and an apoptosis-inducing drug can prevent serious 
pathogen-driven disease.
 Anti-Inflammatory Potential of Apoptotic 
Neutrophils 
 The apoptotic neutrophil is generally functionally qui-
escent. The major secretory and transcriptional process-
es are shut down during apoptosis, which reflects the
anti-inflammatory nature of the apoptotic process  [59] . 
However, the apoptotic neutrophil itself represents an 
important anti-inflammatory stimulus to other cells in-
volved in resolution of inflammation. The phenotype of 
the apoptotic neutrophil changes to produce ‘eat me’ sig-
nals that are recognised by surrounding phagocytes. 
Godson and collaborators have identified the release of 
annexin 1 by apoptotic cells as a soluble signal to promote 
phagocytosis of these cells by macrophages through a li-
poxin receptor (lipoxin A4 receptors)-mediated pathway 
 [61] . The exposure of phosphatidylserine (PS) residues on 
the apoptotic neutrophil membrane allows for greater 
recognition by macrophages, thereby enhancing the 
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clearance of the cells. Interaction of PS with its corre-
sponding, newly identified receptors on macrophages not 
only initiates phagocytosis but also modifies the tran-
scriptional profile of the macrophage, increasing produc-
tion of IL-10 and TGF-  , cytokines associated with re-
solving the inflammatory response and promoting tissue 
repair  [61, 52] . These processes partly help explain the 
benefits associated with extracorporeal photophoresis, 
where a patient’s own leukocytes are isolated, induced to 
undergo apoptosis with the use of photoactivated drugs 
and re-administered via the circulation. This therapy is 
used to enhance the cytotoxic T cell response in the treat-
ment of T cell lymphoma, but clinical benefits have been 
observed in a wide variety of diseases including rheuma-
toid arthritis, inflammatory bowel disease and graft-ver-
sus-host disease, presumably due to the multifaceted role 
of apoptotic cells in the modulation of cytokine response 
and promotion of immune tolerance  [63, 64] .
 It is also apparent that the apoptotic neutrophil has 
excellent LPS-binding capacity thereby reducing the 
LPS stimulation of viable, responding cells. This func-
tion of apoptotic neutrophils has been exploited in an 
interesting study that elegantly demonstrated the ben-
eficial effect of systemic administration of apoptotic hu-
man neutrophils in murine models of septic shock [7]. 
These mice were protected from endotoxin lethality in 
concordance with decreased pro-inflammatory cyto-
kine production, reduced PMN infiltration to the or-
gans and a reduction in serum LPS concentrations. 
Apoptotic cells bound LPS and were removed by macro-
phages promoting an IL-10-driven pro-resolution of in-
flammation response from macrophages and other cells 
influenced by the altered cytokine milieu. This is an ex-
cellent example of an apoptosis-based strategy proving 
beneficial in a model of excessive host response to mi-
crobial infection. 
 The apoptotic death process, as opposed to the necrot-
ic death process, maintains membrane integrity to limit 
release of harmful neutrophil contents. If clearance does 
not follow apoptosis, secondary necrosis can occur, lead-
ing to exacerbated inflammation. Indeed, dysfunction-
ing clearance mechanisms are linked with the pathogen-
esis of many inflammatory and autoimmune diseases 
such as systemic lupus erythematosus. Recently, it has 
been proposed that the dying and necrotic neutrophil has 
anti-inflammatory potential linked to the liberation of 
alpha defensins  [65] . These molecules have complex im-
munomodulatory and anti-microbial effects and are ac-
tively released by activated neutrophils during degranu-
lation at inflammatory sites. Neutrophil necrosis occurs 
by direct cytotoxicity induced by noxious stimuli, by 
apoptotic neutrophils undergoing secondary necrosis re-
sulting from failed clearance or by pore-forming toxins 
such as PVL. The cathelicidin LL-37 has also been shown 
to induce rapid secondary necrosis of neutrophils that 
can potentiate the anti-inflammatory effect of macro-
phages without compromising clearance mechanisms 
 [66] . Although these studies did not show any adverse ef-
fects on macrophage function with suggestion of promo-
tion of a less inflammatory macrophage response, this 
must be weighed against the presence of toxic granule 
contents in the inflammatory milieu that previously had 
always been thought to contribute to host tissue damage. 
These studies clearly demonstrate the balance between 
the pro- and anti-inflammatory effects of neutrophils is 
a precarious one. 
 Not only do Gram-negative and Gram-positive bacte-
ria and their products have an ability to influence apop-
tosis and functional longevity of neutrophils, there is 
abundant evidence indicating that other organisms such 
as viruses and fungi have similar capabilities. For exam-
ple, gliotoxin, an abundant product liberated from fungi 
such as  Aspergillus fumigatus , can induce apoptosis of 
neutrophils by mechanisms including inhibition of NF-
  B  [67] . Neutrophil apoptosis or survival during viral in-
fections may have potentially important consequences in 
either promoting or impairing the ability of the host to 
clear infection but also contribute or reduce infection-as-
sociated pathology. Such examples include the ability of 
respiratory syncytial virus to inhibit neutrophil apopto-
sis, whilst on the other hand viral infections such as HIV 
and influenza A can promote neutrophil apoptosis  [68] .
 Therapeutic Interventions Targeting Neutrophil 
Apoptosis 
 Advances in knowledge of neutrophil biology over the 
past few decades have identified the neutrophil as a key 
immune defence cell, but it is also becoming clear that 
even in death neutrophils have important immunomod-
ulatory functions. There is much left to discover about 
the mechanisms regulating neutrophil life and death. 
Work performed in our laboratory has focussed on the 
use of pharmacological inhibitors of cyclin-dependent 
kinases (CDKi) to drive neutrophil apoptosis in an at-
tempt to resolve inflammatory conditions  [6] . The cyclin-
dependent kinases are enzymes associated with the pro-
gression and regulation of the cell cycle and the CDKi 
drugs have been in development as treatments for cancer, 
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where the cell cycle is clearly an important target  [69] . 
Neutrophils are terminally differentiated cells that one 
would normally consider not requiring of CDKs; how-
ever, measurable levels of various CDKs have been re-
ported. Furthermore, treatment of neutrophils with 
CDKi drugs accelerates the rate of apoptosis through a 
caspase-dependent mechanism  [6] . This has led to some 
exciting research in inflammatory pharmacology, focus-
sing on novel therapeutics to resolve chronic inflamma-
tory conditions by promoting cell-specific apoptotic 
death. In murine models of inflammation, including pas-
sively induced arthritis, bleomycin-induced lung injury 
and carrageenan-elicited acute pleurisy, the CDKi R-
roscovitine significantly improved resolution of inflam-
mation that was associated with an increase in neutrophil 
apoptosis. The benefit of inducing neutrophil apoptosis 
during pneumococcal meningitis was comprehensively 
shown by Koedel et al.  [70] . Neurological deficits caused 
by brain tissue damage are a common finding in survi-
vors of severe meningitis and are linked to increased lon-
gevity of the neutrophil population recruited to the brain. 
The induction of neutrophil apoptosis with R-roscovitine 
in conjunction with antibiotic therapy (ceftriaxone) re-
duced markers of neuronal damage in murine models of 
pneumococcal meningitis. This suggests a possible new 
strategy for the limitation of detrimental neurological 
side effects of meningeal infection as well as opening up 
a more general approach to the management of severe in-
fective disease where a causative role for neutrophils in 
disease pathology can be demonstrated. A dual strategy 
directed against both the causative organism and the in-
flammatory response generated toward that organism 
may be more efficacious than traditional microbe-direct-
ed treatment.
 Targeting the apoptotic pathway to promote resolu-
tion has also been investigated at the level of MAPK sig-
nalling and by targeting proteins of the Bcl-2 family. 
Specific pharmacological inhibition of ERK1/2 involved 
in MAPK signalling augmented resolution of inflam-
mation in a pleurisy model that was linked indirectly 
(by inhibition of the production of neutrophil survival 
factors at the site of inflammation) to an increase in neu-
trophil apoptosis  [71] . Conversely, inhibition of the pro-
apoptotic protein Bax and non-specific inhibition of 
ERK (and COX-2) augmented inflammation in the same 
model by increasing neutrophil longevity. PI3 kinase 
signalling has been implicated in granulocyte recruit-
ment but also has a role in the persistence of neutrophil 
and eosinophil-driven inflammation and is thus recog-
nised as a target for resolution therapies  [72] . The rela-
tively new characterisation of endogenously found lipid-
derived resolvin molecules (aspirin-triggered 15-epi-li-
poxin A4) have also recently been found to influence 
neutrophil apoptosis by suppressing MPO-induced sur-
vival mechanisms with improved resolution of inflam-
mation in lung-injury models  [12, 13] . Macrophage 
clearance of apoptotic neutrophils is another therapeu-
tic target for resolvin compounds that have shown anti-
inflammatory and pro-resolution effects linked to en-
hancement of phagocytosis of apoptotic cells and atten-
uation of macrophage pro-inflammatory cytokine and 
chemokine release  [73] . This demonstrates the multi-
factorial role these compounds can play in promoting 
resolution. Our knowledge of apoptotic regulation in 
neutrophils is increasing and continues to underline the 
importance of the balance of pro- and anti-apoptotic 
Bcl-2 protein family members in the kinetics of apopto-
sis and ultimately the persistence or resolution of in-
flammation. The importance of the key survival pro-
tein, Mcl-1, is demonstrated by the effect of CDKi com-
pounds, as it is down-regulated both in inflammatory 
and cancer models  [6, 74] . Modulation of the pathways 
leading to NF-  B activation has been implicated in the 
resulting destabilisation of levels of Mcl-1 in cancer cells 
 [75, 76] . However, this is not mirrored in inflammatory 
neutrophils where it has been shown that direct activa-
tion of NF-  B is unaffected by CDKi treatment  [77] . In-
flammatory mediators that prolong neutrophil survival 
often work by stabilising Mcl-1 protein levels; therefore, 
it is pertinent that the promotion of apoptosis can over-
come these survival signals that would be in abundance 
during chronic inflammation. Indeed, accelerated neu-
trophil apoptosis was still observed in the presence of 
survival factors LPS, GM-CSF, TNF-  and dcAMP  [6] . 
The effect of CDKis on other cell types involved in in-
flammation must also be considered, in particular with 
regard to the clearance of apoptotic cells by macro-
phages. Uncompromised clearance mechanisms are es-
sential to the success of the paradigm of resolution es-
pecially where the proposed strategy involves increasing 
the apoptotic cell burden. So far, we have shown that 
macrophage recruitment is not adversely affected by 
CDKi treatment [unpubl. data]. Furthermore, the effect 
of CDK inhibition may prove to have beneficial anti-
inflammatory actions as shown by various studies that 
demonstrate a decrease in LPS-stimulated pro-inflam-
matory cytokine production by macrophages over-ex-
pressing the endogenous CDK inhibitor, p21  [78, 79] . 
These findings complement current work in our labora-
tory showing a similar reduction in cytokine produc-
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